Primary Central Nervous System Lymphoma - 01/08/18

Doi : 10.1016/j.ncl.2018.04.008

Kaylyn Sinicrope, MD ^a, Tracy Batchelor, MD, MPH ^a,^b,^c,^⁎
^a Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
^b Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
^c Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA

^∗Corresponding author. Massachusetts General Hospital, Pappas Center for Neuro Oncology, 55 Fruit Street, Boston, MA 02114.Massachusetts General HospitalPappas Center for Neuro Oncology55 Fruit StreetBostonMA02114

Resumen

Primary central nervous system lymphoma (PCNSL) is an aggressive form of non-Hodgkin lymphoma restricted to the central nervous system. Stereotactic biopsy is the gold-standard for diagnosis of PCNSL. Extent of disease evaluation for newly diagnosed PCNSL patients includes brain imaging, eye examination, cerebrospinal fluid assessment, body imaging, and bone marrow biopsy. Methotrexate-based chemotherapy is the standard induction for PCNSL patients. Optimal consolidation therapy for PCNSL has not been defined, with several options feasible, including chemotherapy, high-dose chemotherapy, and autologous stem cell transplantation or whole-brain radiation therapy. Optimal treatment for relapsed and refractory PCNSL has not been defined.

El texto completo de este artículo está disponible en PDF.

Keywords : Primary central nervous system lymphoma, Brain, Non-Hodgkin's lymphoma, Methotrexate